Tumor Marker Index Based on CEA and CA19-9 as a Prognostic Biomarker in Resectable Colon Cancer
Cancer Diagnosis & Prognosis · 01.07.2026 · 6 (4) · 723-728
DOI: 10.21873/cdp.10572 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Diagnosis & Prognosis, online erschienen am 01.07.2026. Verfasst von Tatsufumi Kosuge und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background/Aim: Despite curative resection, the prognosis after surgery for colon cancer varies considerably even among patients within the same TNM stage. There is a need for reliable biomarkers to complement the TNM classification. In pancreatic cancer, tumor markers have been reported as indicators of biological resectability. We therefore focused on tumor markers in colon cancer and investigated the prognostic significance of the tumor marker index (TMI). Patients and Methods: We retrospectively reviewed patients with colon cancer (cecum to rectosigmoid) who underwent curative resection at our institution between 2011 and 2023. Among them, 361 patients without missing clinical or laboratory data were included. TMI was defined as the product of preoperative serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) levels. Patients were stratified into low- and high-TMI groups based on cutoff values determined by receiver operating characteristic (ROC) curve analysis with recurrence as the outcome. Three-year recurrence-free survival (3y-RFS), local recurrence-free survival (3y-LRFS), and distant metastasis-free survival (3y-DMFS) were compared between groups.
Results
The optimal TMI cutoff value was 64, with 226 cases classified into the low-TMI group and 135 cases into the high-TMI group. The 3y-RFS rate was significantly higher in the low-TMI group than in the high-TMI group (94.0% vs. 88.4%, p=0.023). Similarly, the 3y-LRFS rate was significantly better in the low-TMI group (97.7% vs. 95.2%, p=0.044). In contrast, there was no significant difference in 3y-DMFS between the low- and high-TMI groups (95.4% vs. 91.4%, p=0.103).
Conclusion
TMI was associated with postoperative recurrence patterns in curatively resected colon cancer. TMI may serve as a simple and clinically useful biomarker to complement TNM staging and improve risk stratification after curative surgery.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan.
Zitieren
APA
Kosuge, T., Mazaki, J., Kasahara, K., Osakabe, H., Kuwabara, H., Iwasaki, K., Oguma, J., Koga, H., Kanazawa, A., & Nagakawa, Y. (2026). Tumor Marker Index Based on CEA and CA19-9 as a Prognostic Biomarker in Resectable Colon Cancer. Cancer Diagnosis & Prognosis, 6(4), 723-728. https://doi.org/10.21873/cdp.10572
Vancouver
Kosuge T, Mazaki J, Kasahara K, Osakabe H, Kuwabara H, Iwasaki K, et al. Tumor Marker Index Based on CEA and CA19-9 as a Prognostic Biomarker in Resectable Colon Cancer. Cancer Diagnosis & Prognosis. 2026;6(4):723-728. doi:10.21873/cdp.10572
BibTeX
@article{Kosuge2026,
author = {Kosuge, Tatsufumi and Mazaki, Junichi and Kasahara, Kenta and Osakabe, Hiroaki and Kuwabara, Hiroshi and Iwasaki, Kenichi and Oguma, Junya and Koga, Hiroyuki and Kanazawa, Akishige and Nagakawa, Yuichi},
title = {Tumor Marker Index Based on CEA and CA19-9 as a Prognostic Biomarker in Resectable Colon Cancer},
journal = {Cancer Diagnosis & Prognosis},
year = {2026},
volume = {6},
number = {4},
pages = {723--728},
doi = {10.21873/cdp.10572}
}
EUVIMED